BioSpace News Archive

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM Trial of PR006 for Frontotemporal Dementia with GRN Mutations Expected to Initiate Enrollment in Fourth Quarter of 2020 PR001 Receives U.S. FDA Fast Track Designation for Neuronopathic Gaucher Disease

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. “Over the last several months, we have achieved key clinical, regulatory, and corporate milestones that have left us well posit

Continued progress across pipeline of gene therapy programs, including recent IND clearance for AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases Completed rebranding to Sio Gene Therapies as part of corporate transformation aligning corporate structure and governance with current and future business activity Company had $63.2 million of cash and cash equivalents as of September 30, 2020, with sufficient cash runway into Q4 2021

RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview and host 1-on-1 investor meetings at the German Equity Forum (Deutsches Eigenkapital Forum) 2020, one of Europe’s largest investor events, on Tuesday, November 17, 2020, at 9:30 a.m. CET . The presentation